Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

62 results about "Benzoates" patented technology

Benzoates can refer to: Potassium benzoate Sodium benzoate

Preparation method of N-Boc-cis-4-hydroxy-L-proline methyl ester

The invention relates to the technical field of synthesis of organic compounds, and discloses a preparation method of N-Boc-cis-4-hydroxy-L-proline methyl ester, which comprises the following steps: step 1, synthesis of (2S, 4R)-4-p-toluenesulfonyloxy-1, 2-pyrroline dicarboxylic acid-1-tert-butyl ester-2-methyl ester (2): (2S, 4R)-4-hydroxy-1, 2, 4-triazole-2-methyl ester (3) is prepared from (2S, 4R)-4-hydroxy-1, 2, 4-triazole-2-methyl ester and (2S, 4R)-4-p-toluenesulfonyloxy-1, 2-pyrroline dicarboxylic acid-1- The preparation method comprises the following steps: dissolving 1-tert-butyl-2-methyl 2-pyrroline dicarboxylic acid-1-tert-butyl ester-2-methyl ester in dichloromethane; according to the method, (2S, 4R)-4-hydroxy-1, 2-pyrroline dicarboxylic acid-1-tert-butyl-2-methyl ester which is cheap and easy to obtain in the market is adopted as a raw material, after p-benzoylation and acetylation are performed, hydroxyl of the raw material is converted from trans form to cis form, chiral conversion is performed, and finally the target product is synthesized. The used acetate replaces benzoate, the raw materials are cheaper, and the generated by-product acetic acid is more environment-friendly than benzoic acid, so that the method is suitable for large-scale production.
Owner:NANJING ALLY CHEM S&T CO LTD

Quinazoline derivative salt crystal form, preparation method and application

A quinazoline derivative (represented by the formula (I)) salt's crystal form, a preparation method and application are provided; specifically, the hydrochloride crystal form A, B, C, D, F, H, I, Sulphate crystal form A, Maleate crystal form A, Succinate crystal form A, Adipate crystal form A, Glycolate crystal form A, Malate crystal form A, Fumarate Salt crystal form A, besylate crystal form A, B, C, benzoate crystal form A, hippurate crystal form A and oxalate crystal form A of the quinazoline derivative represented by formula (I). The salt crystal form provided by the present invention has good stability, which can be used in the treatment of non-small cell lung cancer brain metastasis, meningeal metastasis, primary brain cancer or glioma, etc., and has good bioavailability, which is of great significance for further research on the efficacy of such solid drugs.
Owner:WEISHANG (SHANGHAI) BIO PHARMA CO LTD

Preparation method of high-quality perovskite thick film for X-ray detector

PendingCN121586379ABenzoic acidSpray coating
The invention discloses a preparation method of a high-quality perovskite thick film for an X-ray detector, and relates to the technical field of radiation detection materials and devices. The preparation method of the thick film comprises the following steps: preparing a precursor solution from lead iodide, cesium iodide, formamidine iodide, methylamine iodide, 4-guanidinobenzoic acid hydrochloride, N, N-dimethylformamide and acetonitrile; a bulk phase functional additive is introduced to optimize a large number of Schottky defects at the grain boundary of the perovskite thick film; depositing onto a heated conductive glass substrate using a spray coating technique; and in combination with a low-temperature solvent atmosphere annealing process, secondary growth of crystal grains and grain boundary healing are promoted, and a large-area polycrystalline thick film can be obtained.
Owner:CHINA UNIV OF MINING & TECH +1

Solid forms of a KV1.3 potassium shaker channel blockers and method of using the same

PCT designated stage expiredWO2025029769A1Nervous disorderOrganic chemistryBenzoic acidGlutaric acid
Solid forms of compound of (2R)-1-[4-[(R)-amino(5-chloro-2-hydroxy-4-methylphenyl)methyl]piperidin-1-yl]-2,3-dihydroxypropan-1-one are described. The solid form may be a pharmaceutically acceptable salt of the compound. The salt may be a carboxylic acid salt, such as a benzoic acid salt, a cinnamic acid salt, or a glutaric acid salt. Pharmaceutical compositions comprising the same and method of using the same in treating a condition such as psoriasis, rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, atopic dermatitis, and alopecia areata are also described.
Owner:ELI LILLY & CO

Green activated covalent organic framework material and benzoic acid recovery method

The invention discloses a method for efficiently activating a prepared covalent organic framework material and recovering benzoic acid, and particularly relates to a method for efficiently activating the prepared covalent organic framework material and recovering benzoic acid by utilizing an acid-base neutralization reaction between an alkaline substance and benzoic anhydride or benzoic acid to generate corresponding salt and activating the prepared covalent organic framework material. Therefore, the covalent organic framework material with high crystallinity, high specific surface area and uniform pore channels is obtained. The invention also provides a method for recovering benzoic acid, which comprises the following steps: by utilizing the property that benzoic acid is slightly soluble in cold water, adding an acidic material and corresponding benzoate into the activated solution to generate benzoic acid, thereby separating out and obtaining benzoic acid with higher purity from the solution.
Owner:NANKAI UNIV

Additives for controlling DVB crosslinking and insoluble polymer formation in styrene processes

A method for reducing fouling in a styrene production process, the method comprising the steps of introducing an additive into a stream containing styrene and a byproduct, divinylbenzene (DVB), wherein the additive comprises at least one compound comprising one or more functional groups selected from the group consisting of amines, alcohols, aminoalcohols, labile C-C, esters, carbamates, aldehydes, ketones, acids, acetates, benzoates, labile hydrogen, and combinations thereof, and having a boiling point greater than or equal to 170°C and within ±10°C, ±20°C, ±30°C, ±40°C, ±50°C, or ±60°C of the boiling point of divinylbenzene (DVB), which is 195°C, wherein the at least one compound is effective in inhibiting crosslinking of the divinylbenzene (DVB). A system for performing the method is also provided.
Owner:FINA TECH INC

Liquid preservative-free detergent composition

The present invention relates to aqueous liquid detergent compositions, wherein the compositions exhibit a high microbial stability without the use of conventional preservatives. The liquid detergent composition of the invention is particularly useful for washing laundry, where a good cleaning performance is needed and where the consumer takes into account the environmental impact of the detergent composition. The composition is boron-free and compres (i) at least one anionic surfactant, preferably selected from the group of sulfonates, ether sulfates, and / or alkyl sulfates, and salts of fatty acids (soap), and combinations thereof, (ii) at least one alkanolamine, preferably ethanolamine, even more preferred monoethanolamine, (iii) at least 50 wt.% water, wherein said composition has a pH value in the range from 6 to 10, and wherein said composition comprises less than 0.05 wt.% of a total amount of conventional preservative(s) of the group comprising benzoic acid, benzoates, phenoxyethanol, sorbates, sulfites, phenoxyethanol, sodium or zinc pyrithione, bronopol, iodopropynylbutylcarbamate, formaldehyde and formaldehyde releaser, glyoxal, glutaral and isothiazolinones. The use of alkanolamines and of the combination of alkanolamines (ii) and anionic surfactant(s) (i) to reduce / inhibit microbial growth in aqueous systems, preferably in aqueous detergent compositions, more preferred in boron-free aqueous detergent compositions, which are free of any conventional preservative, is also disclosed.
Owner:DALLI-WERKE GMBH & CO KG

Deuterated dextromethorphan salt, crystal form, preparation method and application thereof

The invention provides various salt forms of deuterated dextromethorphan as shown in a formula (I) as well as a preparation method and application of the various salt forms. The various salt forms comprise tartrate, citrate, hydrobromide and benzoate. Also provided are various crystal forms of the above salts. The salt has excellent effects in the aspects of stability, biological activity, bioavailability, drug effect and the like, and is suitable for development of pharmaceutical preparations.
Owner:NANJING MINOVA PHARM CO LTD +1

Preparation method of nafamostat mesylate

The invention relates to the technical field of chemical pharmacy, and particularly discloses a preparation method of nafamostat mesylate. The preparation method comprises the following steps: adding 6-amidinyl-2-naphthol mesylate, 4-guanidinobenzoic acid hydrochloride and EDCI into a first solvent, and carrying out condensation reaction; adding a saturated sodium bicarbonate aqueous solution to obtain an intermediate; and adding the intermediate into a second solvent, adding methanesulfonic acid to form salt, and purifying to obtain the nafamostat mesylate. EDCI firstly reacts with a first solvent and is activated, nitrogen atoms with positive charges in EDCI after oxygen atoms on carbonyl carbon of carboxylic acid are activated are positively charged, the electrophilicity of carboxylic acid is increased, an active intermediate is formed, the active intermediate and alcohol are more easily subjected to nucleophilic substitution reaction, and dehydration condensation is performed to form an ester bond. EDCI is used as a condensing agent, so that the production efficiency and yield of the nafamostat mesylate are improved, the purity of the nafamostat mesylate is improved, the impurity content is reduced, the cost is low, and industrial production is easy.
Owner:河北广祥制药有限公司

Benzoic acid salts for treatment of nervous system injuries and disorders

Disclosed are salts of benzoic acid and prodrugs thereof for slowing the progression of or reducing the severity of a symptom associated with a nervous system injury in a subject.
Owner:THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPT OF VETERANS AFFAIRS +1

Salt crystals

To provide a crystal of 2 - (4-acetylbenzyl) - 3 - ((4-fluorophenyl) amino) - 577 - trimethyl-7, 8-dihydro-pyrazolo-imidazo [1, 2-a] 2H [4, 3-e] pyrimidin-4 (5H) - one.SOLUTION: Provided is a crystal of an acid addition salt form selected from, for example, succinate form, citrate form, adipate form, tartrate form (e.g., L-tartrate form), malate form, gluconate form (e.g., D-gluconate form), maleate form, fumarate form, aspartate form (e.g., L-aspartate form), hippurate form, sebacate form, glycolate form, galactarate form, benzoate form, pamoate form, oxalate form and malonate form.SELECTED DRAWING: None
Owner:INTRA CELLULAR THERAPIES INC

Salts of a degradation btk compound and crystalline forms thereof and medical uses thereof

Provided are a salt and / or a crystal form of a compound degrading BTK and preparation and application thereof. The pharmaceutically acceptable salt and crystal form of the compound as shown in formula (I), wherein the pharmaceutically acceptable salt is selected from a maleate salt, a fumarate salt, a hydrogen halide salt (preferably a hydrobromide salt and a hydrochloride salt), a sulfate salt, a phosphate salt, an L-tartrate salt, a citrate salt, an L-malate salt, a hippurate salt, a D-glucuronate salt, a glycolate salt, a mucate salt, a succinate salt, a lactate salt, an orotate salt, a pamoate salt, a glycine salt, an alanine salt, an arginine salt, a cinnamate salt, a benzoate salt, a benzene sulfonate salt, a p-toluene sulfonate salt, an acetate salt, a propionate salt, a valerate salt, a triphenylacetic acid salt, an L-proline salt, a ferulic acid salt, a 2-hydroxyethanesulfonate salt, a mandelate salt, a nitrate salt, a methanesulfonate salt, a malonate salt, a gentisate salt, a salicylate salt, an oxalate salt or a glutarate salt:
Owner:TIBET HAISCO PHARM CO LTD

A preparation method of nafamostat mesylate

The present invention relates to the field of chemical pharmaceutical technology, and specifically discloses a preparation method of nafamostat mesylate. 6-amidino-2-naphthol mesylate, p-guanidinobenzoic acid hydrochloride and EDCI are added to a first solvent to carry out a condensation reaction; then a saturated sodium bicarbonate aqueous solution is added to obtain an intermediate; the intermediate is added to a second solvent, and then methanesulfonic acid is added to form a salt, and purified to obtain nafamostat mesylate. EDCI first reacts with the first solvent to be activated, and the oxygen atom on the carbonyl carbon of the carboxylic acid is positively charged in the activated EDCI, thereby increasing the electrophilicity of the carboxylic acid and forming an active intermediate, making it easier for it to undergo a nucleophilic substitution reaction with an alcohol, and undergoing dehydration condensation to form an ester bond. The present invention uses EDCI as a condensing agent, improves the production efficiency and yield of nafamostat mesylate, improves the purity of nafamostat mesylate, reduces the impurity content, and is low in cost and easy to industrialize.
Owner:河北广祥制药有限公司

Methods of using syntrophus aciditrophicus to produce cyclohexane-1-carboxylate (CHC)

PCT designated stage expiredWO2024258846A1MicroorganismsMicroorganism based processesBenzoic acidCyclohexanecarboxylic acid
A method of producing cyclohexane- 1 -carboxylate (CHC), including providing a growth medium comprising a yeast extract, and a crotonate salt; providing a culture of Syntrophus aciditrophicus (S. aciditrophicus); using the growth medium to initiate growth of the culture of S. aciditrophicus; after the S. aciditrophicus has initiated cell division, adding to the growth medium a benzoate salt, wherein after an incubation period, the CHC produced by the culturing of the S. aciditrophicus in the growth medium is purified. The incubation period may be continued until the amount of CHC in the growth medium has achieved a concentration of at least 1 g / l (7.8 mM).
Owner:THE BOARD OF RGT UNIV OF OKLAHOMA

Application of ningnanmycin salt in prevention and treatment of tobacco mosaic virus

The invention belongs to the technical field of agricultural biology, and particularly relates to application of ningnanmycin salt to prevention and treatment of tobacco mosaic virus diseases. Derivatives of ningnanmycin salts are developed on the basis of ningnanmycin, and the derivatives comprise ningnanmycin acetate, ningnanmycin lactate, ningnanmycin phosphate, ningnanmycin sulfate, ningnanmycin citrate, ningnanmycin benzoate, ningnanmycin oxalate, ningnanmycin hydrochloride, ningnanmycin nitrate and the like. When the ningnanmycin salts are applied to prevention and treatment of the tobacco mosaic viruses, experiments show that compared with ningnanmycin, the ningnanmycin salts have the advantages that the prevention and treatment effect on the tobacco mosaic viruses is remarkably improved, the prevention and treatment effect of moroxydine hydrochloride can be achieved or even exceeded, and the application prospect is good.
Owner:SHAANXI YINGXIN BIOTECHNOLOGY CO LTD

Method of promoting removal of impurities in protein a chromatography

To provide a method for refining polypeptide including an Fc region.SOLUTION: A method includes the steps of: (a) bringing an affinity chromatography matrix in contact with a sample containing (i) polypeptide including an Fc region and (ii) one or more impurities under a condition that polypeptide including an Fc region bonds an affinity chromatography matrix; and (b) cleaning the matrix by a cleaning solution, in which the cleaning solution contains (i) benzoate having the concentration of approximately 0.1 M to approximately 1.0 M, (ii) benzyl alcohol having the concentration of approximately 0.5% to approximately 4% of volume / volume (v / v), and (iii) a buffer agent selected from the group consisting of phosphate, tris, arginine, acetate, citrate and carbonate, where the concentration of the buffer agent is approximately 10 mM to approximately 500 mM, and the cleaning solution has pH of approximately 4.0 to approximately 10.0.SELECTED DRAWING: Figure 1
Owner:GENZYME CORP

Personal care composition preservative level optimization

The present invention relates to a hair care composition comprising from about 8 to about 17% of one or more surfactants; from about 0.01% to about 10% of one or more surfactant soluble anti-dandruff agents; from about 0.01% to about 5% of one or more thickening polymers based on polyacrylate or polyacrylamide; from about 0.02% to about 0.25% of a salicylate or acid; from about 0.02 to about 0.25% of a benzoate or acid, wherein there is a weight ratio of the salicylate or acid to the benzoate or acid of from about 1: 1 to 12.5: 1.
Owner:PROCTER & GAMBLE CO

A method for synthesizing 2-chloro-4-fluorobenzoic acid using 2-chloro-4-fluoroaniline as raw material

The present invention relates to the field of organic synthesis, and in particular to a method for synthesizing 2-chloro-4-fluorobenzoic acid by using 2-chloro-4-fluoroaniline as a raw material, comprising the following steps: 2-chloro-4-fluoroaniline is reacted with cuprous cyanide to generate 2-chloro-4-fluorobenzonitrile through diazotization reaction; 2-chloro-4-fluorobenzonitrile is hydrolyzed under acidic conditions to generate 2-chloro-4-fluorobenzoic acid, or is hydrolyzed under alkaline conditions to generate 2-chloro-4-fluorobenzoate; 2-chloro-4-fluorobenzoate is acidified to obtain 2-chloro-4-fluorobenzoic acid. The preparation method of 2-chloro-4-fluorobenzoic acid provided by the present invention has the advantages of avoiding the use of expensive noble metal catalysts and highly toxic reagents, the reagents used are environmentally friendly, cost is reduced, the process is simplified, the yield is high, the deficiencies of the prior art are overcome, and it is suitable for large-scale industrial production.
Owner:JIANGSU FLAG CHEM IND CO LTD

Methods of preparing chiral benzodiazepinone derivatives

The present invention provides methods of preparing compound of Formula (I), wherein the compounds are represented by the structure of Formula (I) wherein: R1 each is independently F, Cl, Br, I, OCH3, CN or NO2; R2 each is independently identical or different C1-C5 alkyl; n1 is an integer between 1 and 5; and n2 is an integer between 1 and 4. In addition, the present invention provides a compound represented by the following structures: Compound (1a) and Compound (2), wherein X comprises: chloride, acetate, adipate, alginate, ascorbate, aspartate, benzoate, benzenesulfonate, bisulfate, borate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydroiodide, maleate, 2-hydroxyethanesulfonate, lactate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oxalate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, salicylate, succinate, sulfate, sulfonate, tartrate, thiocyanate, toluenesulfonate, or undecanoate salt, or any combination thereof.
Owner:IMMUNOME INC